The PSMA PET radiopharmaceutical 64Cu-SAR-bisPSMA, which previously garnered two FDA fast track designations, more than doubled the detection of PCa lesions in comparison to 68Ga-PSMA-11 in the phase II Co-PSMA trial.
In a recent podcast episode, Jack Andrews, MD, discussed the role of PSMA PET in facilitating more targeted, metastasis-directed therapy for prostate cancer and recent phase 4 research comparing PSMA PET agents in men with low PSA values.
In a new podcast episode, Thomas Hope, MD, shares his insights on glioma imaging and the potential impact of the recently FDA-approved PET agent floretyrosine (18F-FET),
In a new podcast episode, Sharmila Dorbala, MD, MPH, shares her insights on recently published phase 3 research examining the use of the PET/CT radiotracer 124I-evuzamitide for bolstering detection of cardiac amyloidosis.
In the latest episode of her Breast Imaging in Focus series, Manisha Bahl, MD, MPH, FSBI, discussed new research demonstrating that cancer detection rate, sensitivity and positive predictive value (PPV) for digital breast tomosynthesis (DBT) all improved with age.
Uptunity | Aneurysm reportedly identifies suspected saccular brain aneurysms larger than 3 mm on head CTA and provides quantitative comparison between exams to assess changes in known aneurysms over time.